Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.

Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G.

Breast. 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4.

PMID:
24314620
2.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
3.

Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.

Knoop AS, Lænkholm AV, Jensen MB, Nielsen KV, Andersen J, Nielsen D, Ejlertsen B; Danish Breast Cancer Cooperative Group.

Eur J Cancer. 2014 May;50(8):1412-21. doi: 10.1016/j.ejca.2014.02.022. Epub 2014 Mar 24.

PMID:
24675287
4.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
5.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.

PMID:
19130322
6.

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.

Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roché H.

J Clin Oncol. 2009 Jun 10;27(17):2809-15. doi: 10.1200/JCO.2008.18.2808. Epub 2009 Apr 20.

7.

Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.

Torrisi R, Bagnardi V, Rotmensz N, Scarano E, Iorfida M, Veronesi P, Luini A, Viale G, Santoro A, Colleoni M, Goldhirsch A.

Breast Cancer Res Treat. 2011 Apr;126(2):431-41. doi: 10.1007/s10549-010-1340-y. Epub 2011 Jan 8.

PMID:
21221766
8.

Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients.

Montemurro F, Maggiorotto F, Valabrega G, Kubatzki F, Rossi V, Magistris A, Marocco F, Gatti M, Sarotto I, Aglietta M, Ponzone R.

Ann Surg Oncol. 2012 Nov;19(12):3755-61. doi: 10.1245/s10434-012-2505-1. Epub 2012 Jul 18.

PMID:
22805871
9.

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.

Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16.

PMID:
24742606
10.
11.

Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.

Meattini I, Livi L, Saieva C, Franceschini D, Scotti V, Mangoni M, Loi M, Di Brina L, Zei G, Bonomo P, Greto D, Gelain E, Nori J, Sanchez LJ, Orzalesi L, Bianchi S, Biti G.

Clin Breast Cancer. 2013 Aug;13(4):247-53. doi: 10.1016/j.clbc.2013.02.005. Epub 2013 May 15.

PMID:
23684167
12.

Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.

Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM.

Breast Cancer Res Treat. 2013 Jan;137(1):57-67. doi: 10.1007/s10549-012-2296-x. Epub 2012 Nov 8.

PMID:
23135572
13.

Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer.

Sutepvarnon A, Warnnissorn M, Srimuninnimit V.

J Med Assoc Thai. 2013 Feb;96 Suppl 2:S60-6.

PMID:
23590023
14.

Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.

Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, Degirmenci M.

Asian Pac J Cancer Prev. 2015;16(4):1643-9.

15.

Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.

Asian Pac J Cancer Prev. 2012;13(8):4119-23.

16.

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.

Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU.

Clin Breast Cancer. 2013 Aug;13(4):254-63. doi: 10.1016/j.clbc.2013.02.010.

17.

Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.

Gasparini G, Barbareschi M, Boracchi P, Verderio P, Caffo O, Meli S, Dalla Palma P, Marubini E, Bevilacqua P.

Cancer J Sci Am. 1995 Jul-Aug;1(2):131-41.

PMID:
9166466
18.

MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?

McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G.

Ann Surg Oncol. 2011 Oct;18(11):3149-54. doi: 10.1245/s10434-011-1912-z. Epub 2011 Sep 27.

PMID:
21947592
19.

Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.

Grassadonia A, Di Nicola M, Grossi S, Noccioli P, Tavoletta S, Politi R, Angelucci D, Marinelli C, Zilli M, Ausili Cefaro G, Tinari N, De Tursi M, Iezzi L, Cioffi P, Iacobelli S, Natoli C, Cianchetti E.

Ann Surg Oncol. 2014 May;21(5):1575-82. doi: 10.1245/s10434-014-3535-7. Epub 2014 Feb 13.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk